Supplemental material
Leukemia & Lymphoma
Volume 56, 2015 - Issue 10
Related Research Data
The PI3K p110δ Isoform Inhibitor Idelalisib Preferentially Inhibits Human Regulatory T Cell Function
Source:
The American Association of Immunologists
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study
Source:
Springer Science and Business Media LLC
Toxicities in B‑cell non-Hodgkin lymphoma—new agents, new pitfalls
Source:
Springer Science and Business Media LLC
Essential, Nonredundant Role for the Phosphoinositide 3-Kinase p110δ in Signaling by the B-Cell Receptor Complex
Source:
American Society for Microbiology
Idelalisib-induced colitis and skin eruption mimicking graft-versus-host disease
Source:
Springer Science and Business Media LLC
Recommended Guidelines for the Treatment of Cancer Treatment-Induced Diarrhea
Source:
American Society of Clinical Oncology (ASCO)
A Precision B Cell-Targeted Therapeutic Approach to Autoimmunity Caused by Phosphatidylinositol 3-Kinase Pathway Dysregulation.
Source:
The American Association of Immunologists
Pathological assessment of gastrointestinal biopsies from patients with idelalisib-associated diarrhea and colitis.
Source:
Future Medicine Ltd
AKT/PKB signaling: navigating downstream.
Source:
Elsevier Inc.
Idelalisib for the treatment of non-Hodgkin lymphoma
Source:
Informa Healthcare
Effects of Drugs and Excipients on Hydration Status
Source:
MDPI AG
Exploring a Future for PI3K Inhibitors in Chronic Lymphocytic Leukemia.
Source:
Springer Science and Business Media LLC
Follicular lymphoma: Nature Reviews. Disease Primers
Source:
Springer Science and Business Media LLC
PD-1 Inhibitor Gastroenterocolitis Case Series and Appraisal of “Immunomodulatory Gastroenterocolitis”
Source:
Wiley
The Emerging Role of PI3K Inhibitors in the Treatment of Hematological Malignancies: Preclinical Data and Clinical Progress to Date
Source:
Springer Science and Business Media LLC
The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia
Source:
American Society of Hematology
Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma.
Source:
Wiley
Emerging small-molecule treatments for multiple sclerosis: focus on B cells.
Source:
Faculty of 1000 Ltd
Review of targeted therapy in chronic lymphocytic leukemia: what a radiologist needs to know about CT interpretation
Source:
BioMed Central
Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies.
Source:
American Society of Hematology
PI3Kδ and primary immunodeficiencies.
Source:
Nature Publishing Group
Altered macrophage function contributes to colitis in mice defective in the phosphoinositide-3 kinase subunit p110δ
Source:
The University of North Carolina at Chapel Hill University Libraries
A review of the infection pathogenesis and prophylaxis recommendations in patients with chronic lymphocytic leukemia
Source:
Informa UK Limited
Linking provided by
